ApoB vs LDL-C and Non-HDL-C as the Primary Measure of ApoB Lipoprotein-Related Risk: The Debate Is Over

Titled, with rare bluntness, “The Debate Is Over,” this viewpoint declares the ApoB-versus-cholesterol argument settled — and points to the data that closed it.

The clinching evidence came from two huge prospective studies, the UK Biobank and the Copenhagen General Population Study, which compared lipid markers head-to-head in people whose ApoB and LDL-C disagreed. The verdict was consistent: when the two diverge, risk tracks ApoB (particle number), not LDL-C (cholesterol mass). The authors crystallize it in a metaphor — cholesterol is the variable passenger; the ApoB particle is the constant vehicle that lodges in the artery wall and drives atherosclerosis.

The practical takeaway is to make ApoB the primary lipid metric, especially in obesity, metabolic syndrome, and diabetes, where LDL-C systematically understates risk. The resistance is logistical inertia, cost perceptions (now outdated — ApoB assays are cheap and standardized), and guidelines anchored to LDL-C for historical continuity.

We rate the evidence solid-to-strong: a short viewpoint, but resting on large prospective cohorts and Mendelian-randomization causal data. Its clinical significance is very high — declaring ApoB the winner would reclassify risk for millions whose “normal” cholesterol hides a high particle count. (Note: this entry and the “Sniderman et al., 2022” entry in our library are the same JAMA Cardiology article — online-ahead-of-print and print versions of one paper; one could be retired.)